The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with <i>KIT</i> exon 11 + 17/18 mutations-Reference-Cited by-同舟云学术

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Published:2024-09-04 Issue: Volume: Page:1-10
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

George Suzanne¹^ORCID,Blay Jean-Yves²^ORCID,Chi Ping³⁴^ORCID,Jones Robin L⁵^ORCID,Serrano César⁶^ORCID,Somaiah Neeta⁷^ORCID,Gelderblom Hans⁸^ORCID,Zalcberg John R⁹^ORCID,Reichmann William¹⁰^ORCID,Sprott Kam¹⁰^ORCID,Cox Paulina¹⁰^ORCID,Sherman Matthew L¹⁰^ORCID,Ruiz-Soto Rodrigo¹⁰^ORCID,Heinrich Michael C¹¹¹²^ORCID,Bauer Sebastian¹³¹⁴^ORCID

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA 02215, USA

2. Centre Léon Bérard, Lyon, 69008, France

3. Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

4. Weill Cornell Medicine, New York, NY 10065, USA

5. Sarcoma Unit, The Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, SW3 6JJ, UK

6. Vall d'Hebron Institute of Oncology, Barcelona, 08035, Spain

7. The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

8. Leiden University Medical Center, Leiden, 2333 ZA, Netherlands

9. Monash University School of Public Health & Preventive Medicine & Department of Medical Oncology, Alfred Health, Melbourne, Victoria, 3004, Australia

10. Deciphera Pharmaceuticals, LLC, Waltham, MA 02451, USA

11. Portland VA Health Care System, Portland, OR 97239, USA

12. OHSU Knight Cancer Institute, Portland, OR 97239, USA

13. Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, 45147, Germany

14. German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, 45147, Germany

Funder

Deciphera Pharmaceuticals

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14796694.2024.2376521

Reference31 articles.

1. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies

2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastrointestinal Stromal Tumors V. 1.2024©. National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed [March 10, 2024]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or aplication and disclaims any responsibility for their application or use in any way.

3. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications

4. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

5. Gastrointestinal stromal tumors: Pathology and prognosis at different sites